Press Release

Cipla announces Q3 FY1415 Unaudited Consolidated Financial Results

Mumbai, India, 12th Feb 2015: Cipla Limited (BSE: 500087, NSE: CIPLA) today announced its Unaudited Consolidated Financial Results for the quarter ended December 31, 2014 (Q3).

Key Financial & Performance Highlights Q3 FY1415 vis-a-vis Q3 FY1314:
(Current year figures include the relevant results of Cipla’s subsidiaries from the date they became subsidiary of the company and therefore the corresponding figures for the previous period are not comparable).

- Income from operations grew by 6.5% to ₹2,765 cr, up from ₹2,596 cr
- EBITDA grew by 18.5% to ₹554 cr, up from ₹467 cr
- Profit after tax grew by 15.3% to ₹328 cr, up from ₹284 cr
Profit & Loss Highlights:

- Material cost is at 35.8% of income from operations in Q3 FY1415 as compared to 38.5% in Q3 FY1314
- EBIDTA margin as % of income from operations increased by 200 bps at 20% in Q3 FY1415 as compared to Q3 FY1314
- Profit after tax increased by 15.3% to ₹328 cr during Q3 FY1415 as compared to ₹284 cr during Q3 FY1314

Performance Review:

Domestic business:

- Domestic sales grew by 14.2% to ₹1,199 cr during Q3 FY1415, up from ₹1,050 cr during Q3 FY1314
- The growth in domestic sales was largely on account of growth in Respiratory, Anti-infectives, Cardiac and Gastro Intestinal therapies

International business:

- Exports of formulations decreased by 6.2% to ₹1,275 cr during Q3 FY1415, down from ₹1,360 cr during Q3 FY1314
- Exports of APIs declined to ₹151 cr during Q3 FY1415, from ₹158 cr during Q3 FY1314.

About Cipla:

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients. For more than 70 years, Cipla has emerged as one of the most respected pharmaceutical names in India as well as across more than 150 countries. Cipla’s portfolio includes over 1500 products in various therapeutic categories with one quality standard globally. Cipla’s turnover in 2013/14 was 1.7 billion USD.

Whilst delivering a long-term sustainable business, Cipla recognises its duty to provide affordable medicines. Cipla’s emphasis on access for patients was recognized globally for the pioneering role played in HIV/AIDS treatment as the first pharmaceutical company to provide a triple combination anti-retroviral (ARV) in Africa at less than one dollar a day and thereby treating many millions of patients since 2001.

Cipla’s research and development focuses on developing innovative products and drug delivery systems and has given India and the world many ‘firsts’ for instance Triomune. In a tightly regulated environment, the company’s manufacturing facilities have approvals from all the main regulators including US FDA, UKMHRA, WHO, MCC, ANVISA, and PMDA which means the company provides one universal standard both domestically and internationally.

Media Contacts:

Investor Relations
Anant Atal
Contact No.: 022 – 24826450
E-Mail: anant.atal@cipla.com

Corporate Communications
Jaisingh Balakrishnan
Contact No.: +91 9833836185
E Mail: jaisingh.krishnan@cipla.com